Stuttering and Social Phobia – the Main Issues Relating to the Biological Therapy of Social Phobia

• Authors: Czernikiewicz Andrzej , Woźniak Tomasz
• Languages of publication: EN

Abstracts

EN

The article presents the relationship between stuttering and social phobia, which often accompanies stuttering. The first part presents diagnostic indications of social phobia and stuttering. The second part presents the effects of the treatment of social phobia with psychotropics, mainly antidepressants, which translate into a reduction, and in some cases even into the resolution of stuttering symptoms. This fact does not mean that treatment of people who stutter and suffer from social phobia should be limited to administering drugs. The prospect of discontinuing pharmacological treatment and maintaining the patient’s improved mental and social functioning requires the use of a parallel speech-language therapy aimed at enhancing the fluency of speech.

Keywords

EN

stuttering; social phobia; speech-language therapy; pharmacotherapy

• Publisher: Polskie Towarzystwo Logopedyczne
• Journal: Logopedia
• Year: 2018
• Volume: 47 EN
• Issue: 1
• Pages: 169-182

Dates

published

2018-01-01

Contributors

author

Czernikiewicz Andrzej

• Maria Curie-Skłodowska University in Lublin Department of Logopedics and Applied Linguistics

author

Woźniak Tomasz

• Maria Curie-Skłodowska University in Lublin Department of Logopedics and Applied Linguistics

References

• American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders, 5th edition, Washington.
• Baldwin D.S., Asakura S., Koyama T., Hayano T., Hagino A., Reines E., Larsen K., 2016, Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo, “European Neuropsychopharmacology”, 26(6): 1062–1069.
• Blanco C., Heimberg R.G., Schneier F.R., Fresco D.M., Chen H., Turk C.L., Liebowitz M.R., 2010, A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder, “Archives of General Psychiatry”, 67: 286–295.
• Blanco C., Bragdon L., Schneier F.R., Liebowitz M.R., 2014, Psychoparmacology for social anxiety disorder, [in:] Social Anxiety Clinical, Developmental, and Social Perspectives (3rd edition), eds. S.G. Hoffman, P.M. Di Bartolo, Academic Press, London, 626–661.
• Chang S., Zhu D., 2013, Neural network connectivity differences in children who stutter, “Brain”, 136: 3709–3726.
• Chang S., Zhu D., Choo A., Anstat M., 2015, White matter neuroanatomical differences in young children who stutter, “Brain”, 138: 694–711.
• Chouinard G., 2006, The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs, “Journal of Psychiatry & Neuroscience”, 31(3): 168–176.
• Davidson J.R., Potts N.L., Richichi E., Krishnan R., Ford S.M., Smith R., Wilson W.H., 1993, Treatment of social phobia with clonazepam and placebo, “Journal of Clinical Psychopharmacology”, 13: 423–428.
• Davidson J.R., Foa E.B., Huppert J.D., Keefe F.J., Franklin M.E., Compton J.S., Gadde K.M., 2004, Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia, “Archives of General Psychiatry”, 61: 1005–1013.
• Fairbanks J., Pine D.S., Tancer N.K., Dummit S.E., Kentgen L.M., Martin J., Klein, R.G., 1997, Open fluoxetine treatment of mixed anxiety disorders in children and adolescents, “Journal of Child and Adolescent Psychopharmacology”, 7: 17–29.
• Gelernter C.S., Uhde T.W., Cimbolic P., Arnkoff D.B., Vittone B.J., Tancer M.E., Barto J.J., 1991, Cognitive-behavioral and pharmacological treatments of social phobia: A controlled study, “Archives of General Psychiatry”, 48: 938–945.
• Gentile S., 2014, Efficacy of antidepressant medications in children and adolescents with non-obsessive-compulsive disorder anxiety disorders: a systematic assessment, “Expert Opinion on Drug Safety”, 13(6): 735–744.
• Greist J.H., Liu-Dumaw M., Schweizer E., Feltner D., 2011, Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: Results of a double-blind, placebo-controlled 26-week study, “International Clinical Psychopharmacology”, 26(5): 243–251.
• Hoffman S.G., Di Bartolo P.M., 2014, Social Anxiety Clinical, Developmental, and Social Perspectives, (3rd edition), Academic Press, London.
• Hussain F.S., Dobson E.T., Strawn J.R., 2016, Pharmacologic treatment of pediatric anxiety disorders, “Current Treatment Options in Psychiatry”, 3(2): 151–160.
• Isolan L., Pheula G., Salum G.A., Oswald S., Rohde L.A., Manfro G.G., 2007, An open-label trial of escitalopram in children and adolescents with social anxiety disorder, “Journal of Child and Adolescent Psychopharmacology”, 17: 751–759.
• Katschnig H., Stein M.B., Buller R., 1997, On behalf of the international multicenter clinical trial group on moclobemide in social phobia: Moclobemide in social phobia: A double-blind, placebo-controlled clinical study, “European Archives of Psychiatry and Clinical Neuroscience”, 247: 71–78.
• Lader M., Stender K., Burger V., 2004, Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomized, double-blind, placebo-controlled, fixed-dose study, “Depression and Anxiety”, 19: 241–248.
• Liebowitz M.R., 1987, Liebowitz Social Anxiety Scale, “Modern Problems of Pharmacopsychiatry”, 22: 141–173.
• Liebowitz M.R., Gorman J.M., Fyer A.J., Campeas R., Levin A.P., Sandberg D., Hollander E., Papp L., Goetz D.(1988): Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry. Jul;49(7):252-7.
• Liebowitz M.R., Schneier F.R., Campeas R., Hollander E., Hatterer J., Fyer A., Gully R., (1992), Phenelzine versus atenolol in social phobia: A placebo controlled comparison, “Archives of General Psychiatry”, 49: 290–300.
• Liebowitz M.R., DeMartinis N.A., Weihs, K. Londborg P.D., Smith, W.T. Chung, H. Clary, C.M., 2003, Efficacy of sertraline in severe generalized social anxiety disorder: Results of a doubleblind, placebo-controlled study, “Journal of Clinical Psychiatry”, 64: 785–792.
• Liebowitz M.R., Mangano R.M., Bradwejn, J., Asnis G., 2005, A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder, “Journal of Clinical Psychiatry”, 66: 238–247.
• Lydiard R.B., Laraia M.T., Howell E.F., Ballenger J.C., 1988, Alprazolam in the treatment of social phobia, “Journal of Clinical Psychiatry”, 49: 17–19.
• Mayo-Wilson E., Dias S., Mavranezouli I., Kew K., Clark D.M., Ades A.E., Pilling S. (2014) Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2014 Oct;1(5):368-76.
• Montgomery S.A., Nil R., Durr-Pal N., Loft H., Boulenger J.P., 2005, A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder, “Journal of Clinical Psychiatry”, 66: 1270–1278.
• Nader-Mohammadi M.M., Atef-Vahid M.K., Asgharnejad-Farid A.A., Shabani A., Lavasni F., 2015, Short-term dynamic psychotherapy versus sertraline in treatment of social phobia, “Iranian Journal of Psychiatry and Behavioral Sciences”, 9(2): e208.
• Nordahl H.M., Vogel P.A., Morken G., Stiles T.C., Sandvik P., Wells A., 2016, Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: A randomized clinical trial, “Psychotherapy and Psychosomatics”, 85(6): 346–356.
• Nutt D., Ballenger J., 2007, Anxiety Disorders: Panic Disorder and Social Anxiety Disorder, Blackwell Publishing, Oxford.
• Oh K.S., Shin E., Ha J., Shin D., Shin Y., Lim S.W., 2016, Early improvement in one week predicts the treatment response to escitalopram in patients with social anxiety disorder: A preliminary study, “Clinical Psychopharmacology and Neuroscience”, 31, 14(2): 161–167.
• Ontiveros A., 2008, Double-blind controlled study with clonazepam and placebo in social anxiety disorder, “Salud Mental”, 31: 299–306.
• Reich J.R., Yates W., 1988, A pilot study of treatment of social phobia with alprazolam, “American Journal of Psychiatry”, 145: 590–594.
• Rynn M.A., Siqueland L., Rickels K., 2001, Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder, “American Journal of Psychiatry”, 158: 2008–2014.
• Schneier F.R., 1995, Clinical assessment strategies for social phobia, “Psychiatric Annals”, 25: 550–553.
• Schneier F.R., Goetz D., Campeas R., Fallon B., Marshall R., Liebowitz M.R., 1998, Placebocontrolled trial of moclobemide in social phobia, “British Journal of Psychiatry”, 172: 70–77.
• Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C., 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, “Journal of Clinical Psychiatry”, 59(20): 22–33.
• Simon N.M., Worthington J.J., Moshier S.J., Marks E.H., Hoge E.A., Brandes M., Delong H., Pollack M.H., 2010, Duloxetine for the treatment of generalized social anxiety disorder: A preliminary randomized trial of increased dose to optimize response, “CNS Spectrums”, 15(7): 367–373.
• Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I., 1998, Paroxetine treatment of generalized social phobia (social anxiety disorder), “JAMA”, 280: 708–713.
• Stein D.J., Cameron A., Amrein R., Montgomery S.A., 2002a, Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder, “International Journal of Clinical Psychopharmacology”, 17: 161–170.
• Stein D.J., Versiani M., Hair T., Kumar, R., 2002b, Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study, “Archives of General Psychiatry”, 59: 1111–1118.
• Stein M.B., Pollack M.H., Bystritsky A., Kelsey J.E., Mangano R.M., 2005, Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial, “Psychopharmacology”, 177: 280–288.
• Turner S.M., Beidel D.C., Jacob R.G., 1994, Social phobia: A comparison of behavior therapy and atenolol, “Journal of Consulting and Clinical Psychology”, 62: 350–358.
• Van Ameringen M.A., Lane R.M., Walker J.R., Bowen R.C., Chokka P.R., Goldner E.M., Swinson R.P., 2001, Sertraline treatment of generalized social phobia: A 20-week, doubleblind, placebo-controlled study, “American Journal of Psychiatry”, 158: 275–281.
• Versiani M., Mundim F.D., Nardi A.E., Liebowitz M.R., 1988, Tranylcypromine in social phobia, “Journal of Clinical Psychopharmacology”, 8: 279–283.
• Westenberg H.G., Stein D.J., Yang H., Li D., Barbato L.M., 2004, A double-blind placebocontrolled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder, “Journal of Clinical Psychopharmacology”, 24: 49–55.
• Woźniak T., 2015, Diagnoza i terapia osób z zaawansowanym jąkaniem, [in:] Logopedia. Standardy postępowania logopedycznego, red. S. Grabias, J. Panasiuk, T. Woźniak, Wydawnictwo UMCS, Lublin, 797–783.